Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30489126 | 1.00 | KDM4E (0.49) | KDM4ECRHBPCRHR2SMN1; SMN2CNR2 | |
| SCHEMBL2051278 | 0.87 | PTGER4 (0.48) | KDM4ECRHBPCRHR2SMN1; SMN2CNR2 | |
| SCHEMBL4714196 | 0.82 | MAPT (0.60) | KDM4ESMN1; SMN2MEN1KMT2ANOD2 | |
| SCHEMBL29030290 | 0.82 | CNR2 (0.43) | KDM4ECNR2KMT2AALDH1A1HSD17B10 | |
| SCHEMBL18322228 | 0.81 | CNR2 (0.46) | KDM4ECRHBPCRHR2SMN1; SMN2CNR2 | |
| SCHEMBL18322291 | 0.81 | JMJD6 (0.39) | KDM4ECRHBPCRHR2SMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL30954491 | 0.81 | KDM4E (0.42) | KDM4ECRHBPCRHR2SMN1; SMN2CNR2 | |
| SCHEMBL18322239 | 0.81 | KDM4E (0.41) | KDM4ECRHBPCRHR2SMN1; SMN2MEN1 | |
| SCHEMBL30489155 | 0.80 | KDM4E (0.73) | KDM4ECRHBPCRHR2SMN1; SMN2CNR2 | |
| SCHEMBL18322286 | 0.80 | KDM4E (0.73) | KDM4ECRHBPCRHR2SMN1; SMN2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049465-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PFIZER INC. (US) | 2024-07-30 | — | — | US | disclosed |
| WO-2024118524-A1 | AZAINDOLE COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | CEREVEL THERAPEUTICS, LLC (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230002386-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-11472805-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PFIZER, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| EP-3766885-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3766885-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Pfizer Inc (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3310784-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS. | PFIZER (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20190263816-A1 | Tricyclic Compounds And Their Use As Phosphodiesterase Inhibitors | PFIZER INC. (US) | 2019-08-29 | — | — | US | disclosed |
| EP-3310784-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Pfizer Inc (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016203347-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203347-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049465-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE5A | KDM4E 1433/4885CRHBP 3448/4885CRHR2 2134/4885 |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE5A | KDM4E 1433/4885CRHBP 3448/4885CRHR2 2134/4885 |
| US-11472805-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE5A | KDM4E 1433/4885CRHBP 3448/4885CRHR2 2134/4885 |
| US-20190263816-A1 | Tricyclic Compounds And Their Use As Phosphodiesterase Inhibitors | PDE3B, PDE3A, PDE5A | KDM4E 1433/4885CRHBP 3448/4885CRHR2 2134/4885 |
| US-20230002386-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE5A | KDM4E 1433/4885CRHBP 3448/4885CRHR2 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.